The estimated Net Worth of Kyle Guse is at least $2.34 Milion dollars as of 15 November 2017. Mr. Guse owns over 10,000 units of Atossa Therapeutics Inc stock worth over $15,200 and over the last 11 years he sold ATOS stock worth over $0. In addition, he makes $2,329,470 as Chief Financial Officer, General Counsel oraz Secretary at Atossa Therapeutics Inc.
Sign up
Mr. Guse ATOS stock SEC Form 4 insiders trading
Kyle has made over 1 trades of the Atossa Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 10,000 units of ATOS stock worth $3,400 on 15 November 2017.
The largest trade he's ever made was buying 10,000 units of Atossa Therapeutics Inc stock on 15 November 2017 worth over $3,400. On average, Kyle trades about 714 units every 0 days since 2013. As of 15 November 2017 he still owns at least 10,000 units of Atossa Therapeutics Inc stock.
You can see the complete history of Mr. Guse stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Kyle Guse biography
Kyle Guse Esq. J.D. serves as Chief Financial Officer, General Counsel, Secretary of the Company. His experience includes more than 25 years of counseling life sciences and other rapid growth companies through all aspects of finance, corporate governance, securities laws and commercialization. Mr. Guse has practiced law at several of the largest international law firms, including from January 2012 through January 2013 as a partner at Baker Botts LLP and, prior to that, from October 2007 to January 2012, as a partner at McDermott Will & Emery LLP. Before working at McDermott Will & Emery, Mr. Guse previously served as a partner at Heller Ehrman LLP. Mr. Guse began his career as an accountant at Deloitte & Touche and he is an inactive Certified Public Accountant and member of the Bar in the State of California. Mr. Guse earned a B.S. in business administration and an M.B.A. from California State University, Sacramento, and a J.D. from Santa Clara University School of Law.
What is the salary of Kyle Guse?
As the Chief Financial Officer, General Counsel oraz Secretary of Atossa Therapeutics Inc, the total compensation of Kyle Guse at Atossa Therapeutics Inc is $2,329,470. There are 1 executives at Atossa Therapeutics Inc getting paid more, with Steven Quay having the highest compensation of $5,807,920.
How old is Kyle Guse?
Kyle Guse is 56, he's been the Chief Financial Officer, General Counsel oraz Secretary of Atossa Therapeutics Inc since 2013. There are 8 older and no younger executives at Atossa Therapeutics Inc. The oldest executive at Atossa Therapeutics Inc is Stephen Galli, 73, who is the Independent Director.
What's Kyle Guse's mailing address?
Kyle's mailing address filed with the SEC is C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE, WA, 98104.
Insiders trading at Atossa Therapeutics Inc
Over the last 12 years, insiders at Atossa Therapeutics Inc have traded over $114,740 worth of Atossa Therapeutics Inc stock and bought 274,300 units worth $204,285 . The most active insiders traders include Gregory L Weaver, Steven C Quay oraz Shu Chih Chen. On average, Atossa Therapeutics Inc executives and independent directors trade stock every 205 days with the average trade being worth of $38,260. The most recent stock trade was executed by Jonathan Finn on 10 April 2024, trading 25,000 units of ATOS stock currently worth $44,250.
What does Atossa Therapeutics Inc do?
atossa therapeutics, inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the united states. the company's lead program is the development of endoxifen, an active metabolite of tamoxifen which is in phase ii studies to treat and prevent breast cancer. it is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and chimeric antigen receptor t-cell therapies, directly to the site of breast cancer. the company was formerly known as atossa genetics inc. and changed its name to atossa therapeutics, inc. in january 2020. atossa therapeutics, inc. was founded in 2009 and is headquartered in seattle, washington.
What does Atossa Therapeutics Inc's logo look like?
Complete history of Mr. Guse stock trades at Atossa Therapeutics Inc
Atossa Therapeutics Inc executives and stock owners
Atossa Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Steven Quay,
Chairman of the Board, President, Chief Executive Officer -
Kyle Guse,
Chief Financial Officer, General Counsel, Secretary -
Dr. Steven C. Quay,
Chairman, CEO & Pres -
Kyle Guse CPA, Esq., CPA,
CFO, Gen. Counsel & Sec. -
Shu-Chih Chen,
Director -
Gregory Weaver,
Independent Director -
Scott Gordon,
IR Contact Officer -
Richard Steinhart,
Independent Director -
H. Lawrence Remmel,
Independent Director -
Stephen Galli,
Independent Director -
Janet Rose Rea MSPH, RAC,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Delly Behen P.H.R.,
VP of Admin. & HR -
Heather Rees,
VP of Fin. & Accounting -
Janet Rose Rea,
Sr. VP of Regulatory, Quality & Clinical Affairs -
Scott Youmans,
Chief Operating Officer -
Heather Rees,
SVP, Finance and Accounting -
Jonathan Finn,
-
Tessa Cigler,
-
Christopher S. Destro,
Sr. VP, Sales and Marketing -
John Barnhart,
Director -
John E Sawyer,
See Remarks -
Peter J. Carbonaro,
Sr. Vice President, Operations -
Ben R Chen,
Sr. VP of Glob. Reg. Affairs -
Alexander D Cross,
Director